ADMA Biologics Inc Stock News

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through

Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health. Hence, GFF, HNI, ADMA and FRBA are worth buying.

The consensus price target hints at a 28.4% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $5.18, denoting a +0.58% change from the preceding trading day.

RAMSEY, N.J. and BOCA RATON, Fla.

Adma Biologics (ADMA) closed at $5.40 in the latest trading session, marking a +1.31% move from the prior day.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent

IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.

HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.

Adma Biologics (ADMA) closed at $5.18 in the latest trading session, marking a -1.71% move from the prior day.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

Adma Biologics (ADMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.